Tamoxifen citrate encapsulated sustained release liposomes: Preparation and evaluation of physicochemical properties

Scientia Pharmaceutica

Volumn 78, Issue 3, 2010, Pages 507-515

  Layek, Buddhadev ^a,b   Mukherjee, Biswajit ^a  

^a JADAVPUR UNIVERSITY   (India)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Cholesterol; Liposome; Soya phosphatidylcholine; Tamoxifen citrate

Indexed keywords

CHOLESTEROL; LIPOSOME; PHOSPHATIDYLCHOLINE; TAMOXIFEN CITRATE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; HYDRATION; IN VITRO STUDY; LIPID MEMBRANE; LIPOSOMAL DELIVERY; PHYSICAL CHEMISTRY; SOYBEAN; SUSTAINED RELEASE PREPARATION;

EID: 77957377256     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0911-11     Document Type: Article

References (17)

1. O'Reagan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 2002; 3: 207-214. doi:10.1016/S1470-2045(02)00711-8
2. Pappas SG, Jordan VC. Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev. 2002; 21: 311-321. doi:10.1023/A:1021219212638
3. Powles TJ. Anti-oestrogenic chemoprevention of breast cancer-the need to progress. Eur J Cancer. 2003; 39: 572-579. doi:10.1016/S0959-8049(02)00771-2
4. Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Treat. 1999; 54: 255-260. doi:10.1023/A:1006126411210
5. de Lima GR, Facina G, Shida JY, Chein MB, Tanaka P, Dardes RC, Jordan VC, Gebrim LH. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer. 2003; 39: 891-898. doi:10.1016/S0959-8049(02)00530-0
6. Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E, Namer M, Ferrero JM, Milano G. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther. 1996; 59: 401-410. doi:10.1016/S0009-9236(96)90108-3
7. Mukherjee B, Kanupriya, Mahapatra S, Das S, Patra B. Sorbitan monolaurate 20 as a potential skin permeation enhancer in transdermal patches. J Appl Res. 2005; 5: 96-108.
8. Zhao L, Feng S. Effects of lipid chain unsaturation and head group type on molecular interactions between paclitaxel and phospholipids within model biomembrane. J Coll Interfac Sci. 2005; 285: 326-335. doi:10.1016/j.jcis.2004.11.032
9. Lieberman HA, Rieger MM, Banker GS, editors. Liposomes. In: Pharmaceutical Dosage Forms: Disperse Systems. New York: Marcel Dekker, Inc., 1998: 43-86.
10. Pantos A, Tsiourvas D, Paleos CM, Nounesis G. Enhanced Drug Transport from Unilamellar to Multilamellar Liposomes Induced by Molecular Recognition of Their Lipid Membranes. Langmuir 2005; 21: 6696-6702. doi:10.1021/la050211n
11. Gerelli Y, Di Bari MT, Deriu A, Cantu L, Colombo P, Como C, Motta S, Sonvico F, May R. Structure and organization of phospholipid/polysaccharide nanoparticles. J Phys Condens Matter. 2008; 20: 104211. doi:10.1088/0953-8984/20/10/104211
12. Bhatia A, Kumar R, Katare OP. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharm Sci, 2004; 7: 252-259. PMid:15367383
13. Kayyali R, Marriott C, Wisemen H. Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett. 1994; 344: 221-224. doi:10.1016/0014-5793(94)00378-5
14. Chawla JS, Amiji MM. Biodegradable poly(o-caprolactone) nanoparticles for tumortargeted delivery of tamoxifen. Int J Pharm. 2002; 249: 127-138. doi:10.1016/S0378-5173(02)00483-0
15. Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of acyclovir from nano-liposomes and nano-niosomes: An in vitro study. Int J Nanomedicine. 2007; 2: 213-225. PMid:17722549
16. Tiwari SB, Udupa N, Rao BS, Puma D. Thermosensitive liposomes and localized hyperthermia-an effective bimodality approach for tumour management. Indian J Pharmacol. 2000; 32: 214-220.
17. Zhang ZA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. Development and characterization of a novel Cremophor EL free liposome based Paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005; 59: 177-187. doi:10.1016/j.ejpb.2004.06.009